Research assistance

We can help you find what you need. Call us or write us:
US: 800.298.5699
Int'l: +1.240.747.3093
Need help in your search?
 

Matching geography

Reports matching your search in:
 
 

Join Alert Me now!

Receive bi-weekly email alerts on new market research

Sign up today!
 

Infectious Diseases: market research reports

1594

Infectious disease would refer to virus, fungus and bacteria that can cause disease. These conditions are an increasing problem for healthcare systems and governments. Information technology and collaborations in software can help prevent the spread of disease and improve quality of care for patients by developing a system that puts into effect an infectious disease reporting and management system for the 21st century.
This type of disease surveillance is a critical component of public health.

The Canadian government and other organizations have used versions of these data-collection and health sites to detect early signs of the SARS virus in China. The Canadian service, the Global Public Health Intelligence Network, automatically scans Web sites and news sources in seven languages for information on disease outbreaks, contaminated food and water, natural disasters and other health risks around the world. It charges a fee based on the type of organization that accesses it and its usage.

At Harvard Medical School's Children's Hospital Boston, a site called HealthMap crawls through 24,000 Web sites looking for disease-related terms. Results appear on a world map, which has colored markers for dengue fever, avian flu and other diseases.

Disease surveillance networks are not a new activity, they have been in existence since the mid 1960s. The use of information technology allows for more sophisticated data analysis and dissemination of information, worldwide.

RSS Feeds

Infectious Diseases market research reports and industry analysis

< prev 1  2  3  4  5  6  7  8  9  10  next >
Community Acquired Pneumonia – Pipeline Review, H2 2012
12/26/2012 | published by: Global Markets Direct
... development for Community Acquired Pneumonia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Community Acquired Pneumonia. Community Acquired Pneumonia - ...  |  more...
$2,000.00
Plague – Pipeline Review, H2 2012
12/26/2012 | published by: Global Markets Direct
... with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Plague. Plague - Pipeline Review, Half Year is built using data and information ...  |  more...
$2,000.00
Community Acquired Bacterial Pneumonia – Pipeline Review, H2 2012
12/26/2012 | published by: Global Markets Direct
... the therapeutic development for Community Acquired Bacterial Pneumonia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Community Acquired Bacterial Pneumonia. ...  |  more...
$2,000.00
Bacterial Infections – Pipeline Review, H2 2012
12/26/2012 | published by: Global Markets Direct
... Bacterial Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bacterial Infections. Bacterial Infections - Pipeline Review, Half Year is ...  |  more...
$2,000.00
Gram-Negative Bacterial Infections – Pipeline Review, H2 2012
12/26/2012 | published by: Global Markets Direct
... development for Gram-Negative Bacterial Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Gram-Negative Bacterial Infections. Gram-Negative Bacterial Infections - ...  |  more...
$2,000.00
Streptococcus Pneumoniae (Pneumococcus) Infections – Pipeline Review, H2 2012
12/26/2012 | published by: Global Markets Direct
... the therapeutic development for Streptococcus Pneumoniae (Pneumococcus) Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Streptococcus Pneumoniae (Pneumococcus) Infections. ...  |  more...
$2,000.00
H5N1 Infection (Avian Influenza) – Pipeline Review, H2 2012
12/26/2012 | published by: Global Markets Direct
... the therapeutic development for H5N1 Infection (Avian Influenza), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for H5N1 Infection (Avian Influenza). ...  |  more...
$2,000.00
Mobile Health (mHealth) - Enhancing Healthcare and Improving Clinical Outcomes
12/14/2012 | published by: GBI Research
... report examines how mHealth, which is the facilitation of health-related information through mobile-enabled technologies, has been applied by the pharmaceutical industry in drug development and by healthcare providers in the developed and emerging economies to ...  |  more...
$3,500.00
Getting Social With Disease: How Public Health Authorities in Central and Eastern Europe can Improve Outbreak Predictions with Social Media
12/11/2012 | published by: IDC
... whether something "small" like an off-the-shelf analytics application or "large" like a full-scale migration of systems and software to a cloud-based delivery model. Usually this is okay. But in the realm of public health, it ...  |  more...
$1,500.00
Molecular Diagnostics in Infectious Disease Testing
12/1/2012 | published by: TriMark Publications
... one of the most promising areas for growth and innovation. The confluence of breakthroughs in genomics and proteomics--along with the development of microarray devices to measure analytes in the blood--has led to this revolutionary market ...  |  more...
$3,400.00
Fluzone IntraDermal (Seasonal Influenza Vaccines) Forecast and Market Analysis
11/30/2012 | published by: GlobalData
... by influenza virus that results in mild to severe symptoms, such as fever, cold and cough. The market is heavily driven by the sales of prophylactic vaccine treatments to prevent infection. Currently, trivalent intramuscular vaccines ...  |  more...
$6,995.00
FluMist (Seasonal Influenza Vaccines) Forecast and Market Analysis
11/30/2012 | published by: GlobalData
... virus that results in mild to severe symptoms, such as fever, cold and cough. The market is heavily driven by the sales of prophylactic vaccine treatments to prevent infection. Currently, trivalent intramuscular vaccines such as ...  |  more...
$6,995.00
EpiCast Report: Seasonal Influenza Vaccines Epidemiology Forecast to 2022
11/30/2012 | published by: GlobalData
... been shown to reduce influenza morbidity and mortality and high economic burden associated with influenza illness. GlobalData’s epidemiologists expect seasonal influenza vaccination coverage rates for all countries but the UK and China to remain constant ...  |  more...
$6,995.00
PharmaPoint: Seasonal Influenza Vaccines India Drug Forecast and Market Analysis
11/30/2012 | published by: GlobalData
... by influenza virus that results in mild to severe symptoms, such as fever, cold and cough. The market is heavily driven by the sales of prophylactic vaccine treatments to prevent infection. Currently, trivalent intramuscular vaccines ...  |  more...
$4,995.00
PharmaPoint: Seasonal Influenza Vaccines Japan Drug Forecast and Market Analysis
11/30/2012 | published by: GlobalData
... by influenza virus that results in mild to severe symptoms, such as fever, cold and cough. The market is heavily driven by the sales of prophylactic vaccine treatments to prevent infection. Currently, trivalent intramuscular vaccines ...  |  more...
$4,995.00
PharmaPoint: Seasonal Influenza Vaccines Italy Drug Forecast and Market Analysis
11/30/2012 | published by: GlobalData
... by influenza virus that results in mild to severe symptoms, such as fever, cold and cough. The market is heavily driven by the sales of prophylactic vaccine treatments to prevent infection. Currently, trivalent intramuscular vaccines ...  |  more...
$4,995.00
PharmaPoint: Seasonal Influenza Vaccines China Drug Forecast and Market Analysis
11/30/2012 | published by: GlobalData
... by influenza virus that results in mild to severe symptoms, such as fever, cold and cough. The market is heavily driven by the sales of prophylactic vaccine treatments to prevent infection. Currently, trivalent intramuscular vaccines ...  |  more...
$4,995.00
Influenza VLP Vaccine (Seasonal Influenza Vaccines) Forecast and Market Analysis
11/30/2012 | published by: GlobalData
... infection caused by influenza virus that results in mild to severe symptoms, such as fever, cold and cough. The market is heavily driven by the sales of prophylactic vaccine treatments to prevent infection. Currently, trivalent ...  |  more...
$6,995.00
PharmaPoint: Seasonal Influenza Vaccines Spain Drug Forecast and Market Analysis
11/30/2012 | published by: GlobalData
... by influenza virus that results in mild to severe symptoms, such as fever, cold and cough. The market is heavily driven by the sales of prophylactic vaccine treatments to prevent infection. Currently, trivalent intramuscular vaccines ...  |  more...
$4,995.00
PharmaPoint: Seasonal Influenza Vaccines United Kingdom Drug Forecast and Market Analysis
11/30/2012 | published by: GlobalData
... infection caused by influenza virus that results in mild to severe symptoms, such as fever, cold and cough. The market is heavily driven by the sales of prophylactic vaccine treatments to prevent infection. Currently, trivalent ...  |  more...
$4,995.00
PharmaPoint: Seasonal Influenza Vaccines United States Drug Forecast and Market Analysis
11/30/2012 | published by: GlobalData
... infection caused by influenza virus that results in mild to severe symptoms, such as fever, cold and cough. The market is heavily driven by the sales of prophylactic vaccine treatments to prevent infection. Currently, trivalent ...  |  more...
$4,995.00
Afluria (Seasonal Influenza Vaccines) Forecast and Market Analysis
11/30/2012 | published by: GlobalData
... virus that results in mild to severe symptoms, such as fever, cold and cough. The market is heavily driven by the sales of prophylactic vaccine treatments to prevent infection. Currently, trivalent intramuscular vaccines such as ...  |  more...
$6,995.00
ASP7374 (Seasonal Influenza Vaccines) Forecast and Market Analysis
11/30/2012 | published by: GlobalData
... virus that results in mild to severe symptoms, such as fever, cold and cough. The market is heavily driven by the sales of prophylactic vaccine treatments to prevent infection. Currently, trivalent intramuscular vaccines such as ...  |  more...
$6,995.00
FluBlok (Seasonal Influenza Vaccines) Forecast and Market Analysis
11/30/2012 | published by: GlobalData
... virus that results in mild to severe symptoms, such as fever, cold and cough. The market is heavily driven by the sales of prophylactic vaccine treatments to prevent infection. Currently, trivalent intramuscular vaccines such as ...  |  more...
$6,995.00
Fluzone (Seasonal Influenza Vaccines) Forecast and Market Analysis
11/30/2012 | published by: GlobalData
... virus that results in mild to severe symptoms, such as fever, cold and cough. The market is heavily driven by the sales of prophylactic vaccine treatments to prevent infection. Currently, trivalent intramuscular vaccines such as ...  |  more...
$6,995.00
< prev 1  2  3  4  5  6  7  8  9  10  next >